Not giving up on Afrezza, MannKind anticipates US FDA meeting to firm up trials
This article was originally published in Scrip
Executive Summary
MannKind investors are holding their breathes that all goes well during a 10 August meeting with the US FDA, in which the firm will finalize plans for two new pivotal trials of its long-embattled inhaled insulin drug Afrezza (insulin human rDNA origin), which was rejected by the agency in January (scripintelligence, 20 January 2011).